ZCM
ITOS

Ziegler Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Ziegler Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-21,704
Closed -$295K – 407
2023
Q1 		$295K Buy
21,704
+214
+1% +$3.83K 0.01% 378
2022
Q4 		$420K Sell
21,490
-5,818
-21% -$114K 0.02% 354
2022
Q3 		$520K Sell
27,308
-157
-0.6% -$3.62K 0.02% 345
2022
Q2 		$566K Buy
+27,465
New +$652K 0.02% 342

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ziegler Capital Management's ITOS Position: Q2 2023 in Review

Ziegler Capital Management sold out of iTeos Therapeutics (ITOS) in Q2 2023, closing a stake of 21,704 shares — an estimated $295K sold.

Ziegler Capital Management first reported a position in ITOS in Q2 2022 and held it in 4 quarters. The position peaked at $566K in Q2 2022. 146 funds tracked by Wall St. Rank hold ITOS as of Q2 2023.

  • Ziegler Capital Management reported no remaining iTeos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ziegler Capital Management sold 21,704 iTeos Therapeutics shares in Q2 2023, an estimated $295K.
  • Ziegler Capital Management first reported a position in iTeos Therapeutics in Q2 2022 and held it in 4 quarters.
  • Ziegler Capital Management's iTeos Therapeutics position peaked at $566K in Q2 2022.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2023.

Based on Ziegler Capital Management's 13F filing for Q2 2023, filed 25 Jul 2023.